Double versus single high-dose melphalan 200 mg/m2 and autologous stem cell transplantation for multiple myeloma: a region-based study in 484 patients from the Nordic area

Hematol Rev · 2009 · PMC3222243

Europe PMC

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In this trial, a highly significant survival advantage was found for high-dose melphalan therapy, with a prolongation of the median survival from 44 to 62 months. 1 NMSG #7/98 From January 1998 until June 2000, 452 patients <65 years were registered in a similar trial evaluating high-dose melphalan with autologous stem cell support, and using a matched historical patient group as control.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.